---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-010062"
form_type: "8-K"
ticker: "XLO"
cik: "0001840233"
company_name: "Xilio Therapeutics, Inc."
filed_at: "2022-06-16T23:59:59+00:00"
generated_at: "2026-06-25T01:23:33.993438+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Xilio Therapeutics promotes Martin Huber to President; appoints Robert Ross to Board

## Summary
- Martin Huber promoted to President, continues as head of R&D; new employment agreement with $500k base salary and 50% target bonus.
- Huber granted option to purchase 20,000 shares of common stock, vesting over 4 years in equal monthly installments.
- Robert Ross, M.D., appointed to Board as Class II director effective June 15, 2022; also joins Compensation Committee.

## SEC filing metadata
- accession: 0001558370-22-010062
- form_type: 8-K
- ticker: XLO
- cik: 0001840233
- company_name: Xilio Therapeutics, Inc.
- filed_at: 2022-06-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840233/000155837022010062/0001558370-22-010062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840233/000155837022010062/xlo-20220615x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-010062
- JSON: https://secwatch.observer/filing/0001558370-22-010062.json
- Plain text: https://secwatch.observer/filing/0001558370-22-010062.txt

## Key facts
- Executive change
  Robert Ross was appointed as Class II director at Xilio Therapeutics, Inc..
  - Action: appointed
  - Role: Class II director
  source text: Effective June 15, 2022, the Board, on the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Robert Ross, M.D. to the Board as a Class II director of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840233/000155837022010062/0001558370-22-010062-index.htm
- Executive change
  Martin Huber changed role as President at Xilio Therapeutics, Inc..
  - Action: promoted
  - Role: President
  source text: On June 15, 2022, the Board of Directors (the “Board”) of Xilio Therapeutics, Inc. (the “Company”) promoted Martin Huber, M.D., 62, to President of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840233/000155837022010062/0001558370-22-010062-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.